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Abstract. Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC).
We aim to evaluate bevacizumab pharmacokinetics in AGC from the Phase III trial (AVAGAST), and explore
the inﬂuence of patient variables. Bevacizumab concentrations (Cp) were measured in plasma samples taken
following disease progression from 162 patients (7.5 mg/kg every 3 weeks). Predicted Cp [median and 90%
prediction interval] was simulated using the population pharmacokinetic model established for other cancers
(PPK model) and compared to observed Cp. Bevacizumab clearance was estimated using NONMEM and
compared between subgroups. Patient characteristics of AGC are similar to other cancers except for lower body
weight despite higher percentage of males. Eighty-ﬁve percent of observed Cp was below the median predicted
Cp and 38%below the lower boundary of the 90% prediction interval. Median bevacizumab clearance in AGC
was 4.5 versus 3mL/day/kg in other cancers. Bevacizumab clearance was signiﬁcantly faster (p<0.05) in patients
without gastrectomy (n=42) or lower albumin. Clearance appeared to be faster in patients with lower total
protein, higher ECOG scores, more metastatic sites, and poorer response. No signiﬁcant difference in
bevacizumab concentrations and clearancewas observed betweenAsian andNon-Asian patients.AGCpatients
exhibited signiﬁcantly lower bevacizumab exposure due to an approximate 50% increase in clearance versus
other cancers. Bevacizumab is cleared faster in patients without prior gastrectomy. No signiﬁcant difference in
bevacizumab pharmacokinetics was observed between Asian and Non-Asian patients. The underlying
mechanism for faster bevacizumab clearance in AGC is unknown and warrants further research.
KEY WORDS: advanced gastric cancer; bevacizumab; ethnicity; NONMEM; pharmacokinetics.
INTRODUCTION
Bevacizumab (Avastin®, Genentech Inc., South San
Francisco, CA) is a humanized monoclonal immunoglobulin G
(IgG) antibody that speciﬁcally binds and inactivates vascular
endothelial growth factorA (VEGF-A), a key isoform of VEGF
involved in angiogenesis, and a well-characterized pro-angio-
genic factor (1). Bevacizumab causes inhibition of tumor
angiogenesis by blocking VEGF-A from binding to its receptors
and leads to tumor growth inhibition. Bevacizumab, in combi-
nation with standard chemotherapy, was approved to treat
metastatic colorectal cancer, non-small cell lung cancer, breast
cancer, glioblastoma, renal cell carcinoma, and ovarian cancer
(2–7). Furthermore, bevacizumab has been or is being
investigated for pancreatic cancer, hepatic cancer, prostate
cancer, soft-tissue sarcomas, and gastric cancer (GC) (8–13).
Gastric cancer is the fourth most common malignancy in the
world and the third most frequent cancer related death after lung
cancer and liver cancer (http://globocan.iarc.fr/). Bevacizumab
was evaluated in ﬁrst-line advanced gastric cancer (AGC) in a
double-blind randomized Phase III trial Avastin inGastric Cancer
(AVAGAST) with 387 patients in the bevacizumab and placebo
arm, respectively (13). Both median progression-free survival (6.7
versus 5.3 months; hazard ratio, 0.80; p=0.0037) and overall
response rate (46.0% versus 37.4%; p=0.0315) were signiﬁcantly
improved with bevacizumab versus placebo. However, the
primary endpoint of overall survival was not met in the intent-
to-treat population (hazard ratio, 0.87; p=0.1002).
Bevacizumab pharmacokinetics is well established in
phase-I, -II, and -III studies as a single agent or in combination
with chemotherapy for both single- and multiple-dose adminis-
tration with both rich and sparse bevacizumab serum concen-
tration data (14–17). Bevacizumab pharmacokinetics showed
dose linearity within the dose range of 1–20 mg/kg, a slow
clearance, a volume of distribution consistent with limited
extravascular distribution, and a terminal half life of approxi-
mately 20 days. Short-term (e.g., up to 30 days after dose) and
long-term (up to 6 months after dose) pharmacokinetics of
bevacizumab is comparable (17).A population pharmacokinetic
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model has been previously established in metastatic colorectal,
breast, non-small cell lung, and prostate cancer, and showed that
bevacizumab pharmacokinetics is consistent across these can-
cers (15).
However, bevacizumab pharmacokinetics has never been
previously evaluated in GC. The pharmacokinetic analysis of
the data from the randomized double-blind phase III trial
investigating trastuzumab (Herceptin®, Genentech Inc.,
South San Francisco, CA) in combination with chemotherapy
in AGC (ToGA) showed that the exposure of the intravenous
formulation of trastuzumab was signiﬁcantly lower in AGC as
compared to other solid tumors at the same dose (18,19)
although the cause of the altered clearance of the intravenous
formulation of trastuzumab is not fully elucidated and may be
multifactorial. A case–control analysis using the same data
showed that patients with the lowest quartile of the trough
serum concentration of the intravenous formulation of
trastuzumab did not beneﬁt in overall survival, from addition
of trastuzumab treatment to chemotherapy (20).
Furthermore, the pharmacokinetic analysis of the data from
the randomized phase II trial investigating pertuzumab
(Perjeta®, Genentech Inc., South San Francisco, CA) in
combination with chemotherapy and the intravenous formu-
lation of trastuzumab in AGC (JOSHUA) showed that the
mean pertuzumab trough concentration was approximately
37% lower in AGC than that observed in breast cancer at the
same dose (21). These results led to the hypothesis that the
pharmacokinetic properties of antibody drugs may be altered
in AGC, and the pharmacokinetic exposure in AGC may fall
below the concentrations that have been proven efﬁcacious in
other solid tumors such as breast cancer. Therefore, an
investigation of bevacizumab pharmacokinetics in AGC is
warranted.
Pharmacokinetic evaluation of bevacizumab was not
pre-speciﬁed in the AVAGAST protocol. However, plasma
samples for research purposes were collected following
disease progression, allowing for the opportunity to
investigate bevacizumab pharmacokinetics in AGC.
Geographically, GC is concentrated in East Asia. Korea,
Japan, and China account for 60% of new cases and 56% of
death cases every year (http://globocan.iarc.fr/). In recent
multi-regional studies in AGC (13,22,23), Eastern patient
population consistently demonstrated longer overall survival
in both arms compared to the Western patient population. In
addition, the hazard ratios of overall survival between the
treatment and control arm were different in Eastern and
Western patient populations in these trials (Supplement
Table 1). Based on limited pharmacokinetic data, there is
no evidence that bevacizumab pharmacokinetics differ be-
tween Asian and Non-Asian patient populations. However,
no direct comparison has been made. AVAGAST enrolled
almost equal number of Asian (Japan and Korea) and
Non-Asian patients, offering an opportunity for the ﬁrst
time to perform a head-to-head comparison of
bevacizumab pharmacokinetics between Asian and Non-Asian
AGC patients.
Our objectives were to (1) characterize bevacizumab
exposure and pharmacokinetics in AGC, (2) compare
bevacizumab pharmacokinetics between AGC and other
solid tumors, and (3) explore the association between
bevacizumab pharmacokinetics and patient variables.
MATERIALS AND METHODS
Studies and Data Collection
Per AVAGAST protocol (13) (ClinicalTrials.gov identiﬁer:
NCT00548548), patients with previously untreated, histological-
ly conﬁrmed, unresectable, locally advanced or metastatic
adenocarcinoma of the stomach or gastroesophageal junction
were assigned to bevacizumab or placebo in combination with
cisplatin administered for six cycles plus capecitabine adminis-
tered until disease progression or intolerable adverse effects.
Bevacizumab was administered at 7.5 mg/kg every 3 weeks via
intravenous infusion and was discontinued following disease
progression. One plasma sample for research purposes was
collected following disease progression from each patient
whenever possible. Complete dosing records and patient
variables (demographic, prognostic, and biochemical factors)
were collected. The protocol was approved at each participating
site by an independent ethics committee or institutional review
board. All patients were provided written informed consent
before study entry.
Bioanalytical Assay
Bevacizumab concentrations were determined in ethyl-
enediaminetetraacetic acid (EDTA) plasma at Genentech,
Inc. using an enzyme-linked immunosorbent assay (ELISA)
adapted from the existing serum ELISA for bevacizumab
(24). Similar to the serum ELISA, the EDTA plasma assay
uses recombinant human VEGF for capture of circulating
bevacizumab onto ELISA plates, and the same polyclonal
goat anti-human IgG Fc antibody conjugated to horseradish
peroxidase for detection. The sample minimal dilution in both
PK assays is 1:100, done in assay buffer. The assay was
qualiﬁed for the testing of human plasma samples with a
lower limit of quantiﬁcation of 78 ng/mL. Additional qualiﬁ-
cation experiments showed that the assay accurately quan-
tiﬁes bevacizumab spiked into human plasma samples of
individual donors, obtained from a commercial source
(Bioreclamation, LLC; Baltimore, MD). Overall, the assay
presented adequate accuracy, precision, dilution linearity, and
speciﬁcity. The presence of VEGF in samples, at expected
physiological concentrations, did not markedly interfere in
the quantiﬁcation of bevacizumab. In addition to following
the same assay format as the serum assay, the standard curve
of the plasma assay was shown to be superimposable to the
standard curve of the serum assay. Furthermore, both assays
were found to have comparable performance by all param-
eters assessed, including assay sensitivity, dilution linearity,
target (VEGF) interference, and spike recovery in matrix.
Reference PPK Model
A population pharmacokinetic analysis (reference PPK
model) has been previously conducted using pooled data
from 533 patients in metastatic colorectal, breast, non-small
cell lung, and prostate cancer (15), and then updated with
ﬁrst-order conditional estimation method with η–ε interaction
(FOCE INTER) method. Model details are summarized in
Supplement Table 2.
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Pharmacokinetic Analysis
Visual predictive check (VPC) and Empirical Bayes
estimation were performed in NONMEM 7.1.2 (ICON
Development Solutions, Dublin, Ireland) using FOCE INTER
method. All other analysis and graphing were performed using
R 2.15.1 (25). Clinically relevant patient variables were selected
a priori (Table I).
In the VPC, expected (simulated) bevacizumab pharma-
cokinetic concentration-versus-time proﬁles [median and 90%
prediction interval (PI)] were simulated (1,500 times) using
the ﬁnal covariate reference PPK model and the patient
variables collected in AVAGAST, and then compared to the
observed bevacizumab concentrations in AVAGAST. The
individual predicted bevacizumab concentration at the time of
sampling was also calculated for each patient using the ﬁnal
covariate reference PPK model, and was compared to the
observed data.
In the Empirical Bayes estimation, posterior Bayes phar-
macokinetic parameter estimates were obtained by ﬁtting the
reference PPK model to the observed data with the estimation
option MAXEVALS set to 0 and POSTHOC. The resulting
individual bevacizumab pharmacokinetic parameter estimates
were comparedwith those from the reference PPKmodel (other
solid tumors), and were compared between patient subgroups
stratiﬁed by patient variables (demographic, prognostic, and
biochemical factors). The expected bevacizumab pharmacoki-
netic parameters were calculated for each patient using the ﬁnal
covariate reference PPK model (“expected” parameters), and
compared to the estimated bevacizumab pharmacokinetic
parameters based on observed data (“observed” parameters).
Statistical Analysis
All statistical analysis and graphing were performed
using R 2.15.1 (25). Log transformation was applied when
the data was log-normally distributed. The relationship
between pharmacokinetic parameters and continuous patient
variables was examined by linear regression analysis. The
relationship with dichotomous variables was evaluated using
unpaired two-tailed Student’s t test or one-way analysis of
variance. The observed and expected (simulated) concentra-
tions or pharmacokinetic parameters in the same patient were
compared using paired two-tailed Student’s t test. In addition,
the ratios of geometric means were calculated. The 95%
conﬁdence intervals (CI) for the ratios of geometric means
were obtained by back transformation.
RESULTS
Patient Population and Characteristics
A total of 182 pharmacokinetic plasma samples were
able to be collected following disease progression from 182
patients in AVAGAST (47% of the patients in the
bevacizumab arm). The sampling time varied from days 2 to
394 after the last dose of bevacizumab. Bevacizumab
concentrations were below lower limit of quantiﬁcation
(LLOQ) in 20 samples, leaving 162 evaluable pharmacoki-
netic samples (Fig. 1a). Patient characteristics of the 162
patients were consistent with the whole population in
AVAGAST (Table I). Most of the patient characteristics of
the 162 patients were similar with the patient population in
the reference PPK model except for substantially lower body
weight (59.9 versus 74 kg) and higher percentage of males
(67.3% versus 43.8%). The sampling time was within 50 days
after the last bevacizumab dose in 93.2% (n=151) of the 162
evaluable patients.
Visual Predictive Check
The median number of bevacizumab doses received was 7,
and the 25th and 75th percentile was 5 and 10 doses. Therefore,
steady state was assumed. The observed bevacizumab concen-
trations were signiﬁcantly below the expected (simulated)
bevacizumab pharmacokinetic concentration-versus-time pro-
ﬁles [median and 90% PI] (Fig. 1a, b). Only 1 out of the 162
observed concentrations was above the upper boundary of the
90% PI, 85.2% of the observed concentrations fell below the
median, and 38.3% below the lower boundary of the 90% PI.
The individual observed and expected bevacizumab
concentration was compared in Fig. 1c. The observed
Table I. Patient Characteristics
Gastric cancer patients (n=162)
Age (years) 58 (28∼81)
Body weight (kg) 59.9 (35.7∼100.2)
Serum albumin (g/L) 39 (27∼48.3)
Total protein (g/L) 68 (49∼85.4)
ECOG score 0/1/2 47.5%:45.7%:6.8%
(77:74:11)
Gender (male/female) 67.3%:32.7% (109:53)
Baseline plasma VEGF-A (pg/mL) 110.2 (20∼1,868)
Lactate dehydrogenase (U/L) 220 (50∼2,675)
Disease control rate (SD/PR/CR) 82.7% (134)
Number of metastatic sites >1 69.8% (111)
Prior gastrectomy (no/yes) 74.1% (120)
Asian 62.3% (101)




Prior chemotherapy 6% (9)
Location of primary tumor:
gastroesophageal junction/stomach
14%:86% (22:140)
Extent of disease: locally
advanced/metastatic
2.5%:97.5% (4:158)
Stage IIIA/IV 2%:96% (3:156)
Liver metastases 36.4% (59)
Bone metastases 4.9% (8)
HER2-negative 82.7% (134)
Sampling day after the last dose 25 (2∼284)
Number of doses received 7 (1∼21)
Reference PPK model
Age (years) 59 (21∼88)
Body weight (kg) 74 (49∼114)
Serum albumin (g/L) 37 (29∼44)
Total protein (g/L) 72 (62∼83)
ECOG 0:1:2 54.0%:44.2%:1.8%
Gender (male/female) 43.8%:56.2%
All values are expressed as median (range) or percentage of the patients
(number of the patients)
ECOG Eastern Cooperative Oncology Group, VEGF-A vascular
endothelial growth factor A, SD stable disease, PR partial responses,
CR complete responses, PPK population pharmacokinetic
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concentrations were below the expected concentrations in
82% of the patients (n=133). The observed bevacizumab
concentrations are signiﬁcantly lower than expected by 47%
on average (p<0.0001, paired t test). The ratio of geometric
means of observed concentrations and expected contractions
was 0.52 (95% CI=0.46 to 0.60).
Empirical Bayes Estimation
The individual pharmacokinetic parameters were esti-
mated with the covariate for chemotherapy set to 1. Due to
the signiﬁcant difference in body weight and gender percent-
age between these 162 AGC patients and the reference
patient population (other solid tumors), weight normalization
was applied whenever appropriate. Median weight-normal-
ized clearance values in AGC patients (4.5 mL/day/kg) were
50% higher than other cancer types (3 mL/day/kg).
Figure 2a compared the individual clearance that was
estimated based on observed data (noted as “observed”) and
expected based on the reference PPK model (noted as
“expected”). The “observed” clearance values are signiﬁcant-
ly higher than the “expected” (p<0.0001, paired t test), and is
above expected in 82% of the patients (Fig. 2b). The ratio of
geometric means of “expected” clearance and “observed”
clearance values was 0.77 (95% CI=0.74 to 0.81).
Impact of Patient Variables on Bevacizumab Exposure
and Clearance
Among all the patient variables (demographic, prognos-
tic, and biochemical factors) evaluated, baseline body weight
exhibited the most signiﬁcant correlation with bevacizumab
clearance (p<0.0001, Fig. 3a). Bevacizumab clearance signif-
icantly increased with increasing body weight, and therefore,
weight-normalized clearance was correlated to other patient
variables instead of absolute clearance. Figure 3b, c demon-
strated that bevacizumab clearance was signiﬁcantly faster
(p=0.0014) in patients without prior gastrectomy (median=
4.72 mL/day/kg, n=120) than those with gastrectomy (medi-
an=3.75 mL/day/kg, n=42) with a ratio of geometric means of
1.19 (95% CI=1.07 to 1.32). Bevacizumab weight-normalized
clearance signiﬁcantly decreases with increasing baseline
albumin (p<0.0001), and appeared to be faster in patients
with lower total protein levels, higher Eastern Cooperative
Oncology Group (ECOG) scores, more metastatic sites, and
poorer response (Supplement Figures), but these correla-
tions did not reach statistical signiﬁcance. No statistically
signiﬁcant correlation was observed between bevacizumab
clearance and tumor location (gastroesophageal junction versus
stomach), type of gastric cancer (diffuse, intestinal, or mixed),
baseline plasma VEGF-A, baseline lactate dehydrogenase, liver
metastases, HER2 status, or gender.
Comparison of relevant patient characteristics between
the Asian and Non-Asian patients is summarized in Table II.
Body weight was signiﬁcantly lower (p<0.0001) in Asian
patients. No statistically signiﬁcant difference was observed in
other patient variables between Asian and Non-Asian
patients.
As shown in Fig. 1a, b, no signiﬁcant separation of
bevacizumab plasma concentrations was observed between
Asian and Non-Asian patients. No signiﬁcant pattern was
observed between Asian and Non-Asian patients in term of
the difference between observed and expected (simulated
Fig. 1. Visual predictive check (VPC) comparing observed and
expected (simulated) bevacizumab concentrations. Only the 151 patients
with a sampling time within 50 days after the last bevacizumab dose are
shown (93.2% of the 162 evaluable patients)
Fig. 2. Comparison of individual bevacizumab clearance that is
predicted (expected) based on the reference population pharmacoki-
netic model and estimated based on observed data via Empirical
Bayes estimation. Solid symbols represent the mean. Hollow symbols
represent individual data. Ref: reference
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based on the reference PPK model) bevacizumab concentra-
tions (Fig. 1c) and weight-normalized clearance (Fig. 2b).
Statistical comparison of bevacizumab trough concentra-
tions and clearance between Asian and Non-Asian AGC
patients is summarized in Fig. 4. Due to the large variability
in sampling time after the last dose of bevacizumab, only
bevacizumab concentrations collected within a reasonable
time window around the end of a dosing cycle (21 days after
dose) were included in the analysis. Bevacizumab concentra-
tions collected between day 19 and day 23 (n=56) averaged
41.5 and 40.7 mcg/mL in Asian (n=33) and Non-Asian (n=
23) patients, respectively, and no statistically signiﬁcant
difference was observed with a p value of 0.4761 (Fig. 4a).
The ratio of geometric means of concentrations in Asian and
Non-Asian patients was 1.16 (95% CI=0.76 to 1.77). Altering
the time window yielded similar results.
Weight-normalized bevacizumab clearance averaged 4.73
and 4.61 mL/day/kg in Asian (n=101) and Non-Asian (n=61)
patients, respectively, and no statistically signiﬁcant difference
was observed with a p value of 0.3652 (Fig. 4b). The ratio of
geometric means of concentrations in Asian and Non-Asian
patients was 1.05 (95% CI=0.95 to 1.16).
DISCUSSION
This is the ﬁrst study investigating bevacizumab pharma-
cokinetic behavior and exposure in advanced gastric cancer
(AGC). This analysis attempted to address two critical ques-
tions: (1) is bevacizumab exposure and pharmacokinetics
different in AGC and other solid tumors and (2) which patient
variables (demographic, prognostic, and biochemical factors)
inﬂuence bevacizumab exposure and pharmacokinetics in
Fig. 3. Signiﬁcant correlation of bevacizumab clearance with patient variables a baseline body weight, b
gastrectomy, and c baseline serum albumin. Solid symbols represent the mean. Hollow symbols represent
individual data. The clearance in other solid tumors was calculated by taking into the account the covariate
values in this study
Table II. Comparison of Patient Characteristics between Asian and




Age (years) 58 (28∼76) 58 (31∼81)
Body weight (kg) 55.1 (35.7∼95.4) 67 (40∼100.2)
Serum albumin (g/L) 38 (27∼47) 40 (29∼48.3)
Total protein (g/L) 68 (49∼81) 68 (56∼85.4)
Male/female 68.3%:31.7% 65.6%:34.4%
Gastrectomy (no/yes) 71.3%:28.7% 78.7%:21.3%
Number of metastatic sites >1 67.0% 74.6%
Sampling day after the last dose 26 (2∼99) 25 (3∼284)
Number of doses received 7 (1∼21) 8 (2∼21)
All values are expressed as median (range) or percentage of the patients
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AGC?Our study demonstrated signiﬁcantly lower bevacizumab
pharmacokinetic exposure in patients with AGC and an
approximate 50% increase in clearance versus other solid
tumors, consistent with observations in the intravenous formu-
lation of trastuzumab (18,19) and pertuzumab (21).
Bevacizumab was also found to be cleared signiﬁcantly faster
in AGC patients without prior gastrectomy. Bevacizumab
exposure and clearance was not signiﬁcantly different between
Asian and Non-Asian AGC patients.
To date, the existing reference population pharmacoki-
netic (PPK) model was the most comprehensive pharmaco-
kinetic evaluation of bevacizumab in various solid tumors;
however, AGC was not included in the PPK model, as clinical
trials had not been performed in AGC by the time when the
PPK model was developed. The PPK model contained data
that represented both bevacizumab as a single agent or in
combination with chemotherapy, both single- and multiple-
dose administration, and both rich and sparse data.
Therefore, it was an ideal reference population and model
to evaluate the difference in bevacizumab pharmacokinetics
between AGC and other solid tumors. The ﬁnal model has
incorporated all relevant patient variables that have a
signiﬁcant impact on bevacizumab pharmacokinetics, and
therefore, eliminated the inﬂuence of the possible imbalance
of patient characteristics between AGC patients in this
analysis and the reference patient population (other solid
tumors).
Two distinct approaches were employed to compare
bevacizumab pharmacokinetics in AGC with other solid
tumors. One approach was the visual predictive check
(VPC) to compare observed bevacizumab concentrations in
AGC patients against expected concentrations assuming the
same bevacizumab pharmacokinetics in AGC as in other
solid tumors (reference PPK model). The other approach was
Empirical Bayes estimation to compare estimated
bevacizumab pharmacokinetic parameters based on observed
data against expected parameters assuming same
bevacizumab pharmacokinetics in AGC as in other solid
tumors.
The VPC showed strong evidence that AGC patients
were underexposed to bevacizumab as compared to other
solid tumors when given the same dose (Fig. 1). The observed
bevacizumab concentrations were signiﬁcantly lower than
expected by 47% on average (p<0.0001). The observed
concentrations were below the expected concentrations in
majority of the patients.
The Empirical Bayes estimation suggested that faster
clearance is the potential cause of the bevacizumab
underexposure in AGC. Median weight-normalized clear-
ance was 4.5 mL/day/kg in AVAGAST, which is approx-
imately 50% faster than other solid tumors (3 mL/day/kg).
The estimated clearance based on observed AVAGAST
data is signiﬁcantly faster than expected (p<0.0001,
Fig. 2a), and is above expected in majority of the patients
(Fig. 2b).
The limitation of Empirical Bayes estimation is that
volume of distribution (Vd) cannot be reliably estimated
due to the sparse sampling, and therefore, the variation in
the observed concentrations is predominantly translated
into the variation in clearance. Therefore, we could not
reliably compare Vd in AGC against other solid tumor or
associate Vd with ethnicity or patient variables in AGC.
However, Vd of bevacizumab carries small inter-individual
variability and is roughly equal to the plasma volume (15).
Therefore, it is reasonable to focus on the clearance of
bevacizumab.
The underlying mechanism for the lower exposure and
faster clearance of bevacizumab in AGC is not clear. One
possible hypothesis is that cancer cachexia may cause
bevacizumab and IgG monoclonal antibody to be consumed as
source of protein, especially considering that the gastrointestinal
dysfunction in AGC patients may signiﬁcantly reduce the
absorption of nutrients. However, no cachexia was observed in
the patient population in this analysis. Another possible hypoth-
esis is that the gastric dysfunction and gastrectomy in AGC
Fig. 4. Comparison of bevacizumab exposure and clearance between
Asian and Non-Asian patients a bevacizumab through concentrations
collected between days 19 and 23 after the last dose and b bevacizumab
clearance. Solid symbols represent the mean. Hollow symbols represent
individual data. The clearance in other solid tumors was calculated by
taking into the account the covariate values in this study
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patients may alter IgG elimination via catabolic mechanisms or
altered blood ﬂow. Further research is warranted to investigate
the underlying mechanism. Pharmacokinetic drug–drug interac-
tion (DDI) between bevacizumab and cisplatin/capecitabine is
unlikely the cause because such DDI was not observed in
previous clinical trials (data unpublished). In general, small-
molecule drugs (e.g., chemotherapy agents) and monoclonal
antibodies (e.g., bevacizumab) do not share clearance
pathways. Therefore, it is not expected that chemotherapy
agents would have any potential interactions with or direct
alterations of the clearance or exposure of monoclonal antibod-
ies. Target-mediated disposition is also unlikely the cause
because the molar concentration of bevacizumab is thousands
of times higher than that of the target (VEGF-A), resulting in
target saturation.
Our observation that baseline body weight and albumin
are signiﬁcantly associated with bevacizumab clearance in
AGC is consistent with previous ﬁndings in other solid
tumors (14,15). It is well known that clearance of other IgG
antibodies is faster in patients with lower serum albumin
levels (26). This effect may be due to the mechanism for
albumin turnover, which is also mediated by FcRn (neonatal
Fc receptor) recycling (27,28). Therefore, low albumin levels
might reﬂect decreased efﬁciency of FcRn catabolic/recycling
capability, which correlates to faster bevacizumab clearance
leading to lower exposure.
Gastrectomy is a unique patient variable to AGC. It is
well known that patients with prior gastrectomy have better
clinical outcomes and better health status. Our analysis
demonstrated that bevacizumab clearance was signiﬁcantly
faster (p=0.0014) in patients without prior gastrectomy, likely
because gastrectomy results in or indicates better patient
health status, while it is well known that clearance of
bevacizumab is slower in patients with better health status.
Any other underlying mechanism responsible for faster
bevacizumab clearance in patients without prior gastrectomy
is unknown and warrants further research. Our study also
demonstrated that bevacizumab clearance appeared to be
faster in patients with lower total protein, higher ECOG
scores, more metastatic sites and poorer response
(Supplement Figures), but these correlations did not reach
statistical signiﬁcance, likely due to small sample size. All the
signiﬁcant correlations between bevacizumab clearance and
patient variables were consistent when the base reference
PPK model or the ﬁnal covariate PPK model was used to
estimate the clearance.
In recent several multi-regional studies of AGC, longer
overall survival was observed in Asian patients, and hazard
ratios of overall survival between the treatment and control arm
were different in Asian and Non-Asian patients (Supplement
Table 1). It was unknown whether these differences could result
in different bevacizumab pharmacokinetics between Asian and
Non-Asian patients, or vice versa. Our analysis did not
demonstrate different bevacizumab exposure or clearance
between Asian and Non-Asian patients (Figs. 1, 2b, and 4).
Relevant patient characteristics were well balanced, especially
all the variables that were found signiﬁcantly correlated with
weight-normalized clearance of bevacizumab (albumin and
gastrectomy). It is worth mentioning that the absolute
bevacizumab clearance (mL/day) was signiﬁcantly lower in
Asian AGC patients (p=0.0134), but body weight was also
signiﬁcantly lower in Asian AGC patients (p<0.0001), and no
difference in weight-normalized clearance was observed be-
tween Asian and Non-Asian patients. This suggested that the
difference in bevacizumab absolute clearance by ethnicity is
most likely caused by the body weight difference betweenAsian
and Non-Asian patients.
Our analysis has several limitations. First of all, there was
only one sample from each patient, which made it impossible
to perform comprehensive population pharmacokinetic
modeling with covariate analysis. However, the two ap-
proaches we employed (VPC and Empirical Bayes estima-
tion) successfully overcame this challenge of sparse sampling
and adequately addressed the primary scientiﬁc questions
(difference in bevacizumab pharmacokinetics between AGC
and other solid tumors and between Asian and Non-Asian
AGC patients). Secondly, the sample was taken at random
times after the last dose of bevacizumab instead of nominal
time, resulting in a large variability in sampling time. This
made it challenging to compare bevacizumab concentrations
between subgroups due to the decline of concentration over
time. Fortunately, the actual time of sampling was recorded,
and we were able to adjust for this variability in sampling
time by only comparing bevacizumab concentrations collect-
ed within a relatively narrow time window around the end of
a dosing cycle (21 days after dose), such as days 19 to 23,
which is adequate given that bevacizumab has a long half
life of 20 days. The pharmacokinetic analysis was also
repeated in patients who received more than ﬁve or six
doses at the time of sampling in order to make sure that
the assumption of steady state is valid. The results are
very similar to the current analysis and did not change the
conclusion. Finally, the number of patients with evaluable
pharmacokinetic samples was relatively small, partly due
to the high death rate of AGC patients and partly due to
the random sampling time as bevacizumab concentrations
were below LLOQ in many samples that were collected
too long after the last bevacizumab dose. However, all
efforts were made to collect samples from all patients, and 47%
of the patients in the bevacizumab arm were able to contribute
samples.
In conclusion, AGC patients exhibited signiﬁcantly lower
bevacizumab exposure due to an approximate 50% increase
in clearance versus other solid tumors, consistent with
observations in the intravenous formulation of trastuzumab
(18,19) and pertuzumab (21). Bevacizumab is cleared faster in
patients without prior gastrectomy. No signiﬁcant difference
in bevacizumab pharmacokinetics was observed between
Asian and Non-Asian patients. The low bevacizumab expo-
sure in AGC could potentially fall below the drug exposure
that has been proven efﬁcacious in other solid tumors,
especially considering that the lowest approved clinical dosing
regimen for bevacizumab (7.5 mg/kg every 3 weeks) was used
in AVAGAST. The underlying mechanism for faster
bevacizumab clearance in AGC patients and especially in
AGC patients without gastrectomy is unknown and warrants
further research.
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